(Reissue of PAR-18-617) The purpose of this funding opportunity announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Technology Transfer (STTR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The projects must focus on products related to the mission and goals of the NINDS and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies. Only STTR Phase II and Fast-Track applications are supported under this program. STTR Phase I applications are only accepted as part of a Fast-track application.
Find Funding Opportunities
NIH Extramural Response to Natural Disasters and Other Emergencies
In emergency situations, the NIH’s immediate concern is for the health and safety of people and animals in the programs we oversee. Visit the NIH Extramural Response to Natural Disasters and Other Emergencies web page for biomedical research community resources, including NIH Guide Notices and other information of particular relevance to investigators and their institutions, links to web pages listing NIH’s response to certain major events (past and present); and links to similar web sites from other Federal agencies.
COVID-19 Funding Notices | Approved Initiative Concepts | Research Opportunity Announcements
All NINDS-related notices of funding opportunities (NOFOs), request for applications (RFAs), program announcements (PAs), and other NIH Guide announcements are listed. Search the Closed Opportunities tab to find expired opportunities. Search the Notices tab to find all Notices.
Learn more about award types and program directors and managers.
NINDS has a number of open positions for researchers and clinicians to contribute to exciting neuroscience programs - APPLY NOW!
For more focused results add quotes to indicate parameters. Example format: "search term".
NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
Expiration Date: Sunday, September 6, 2026
NOFO Number: PAR-24-044
Monday, November 27, 2023
Notice Type: PAR
NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required)
Expiration Date: Saturday, March 7, 2026
NOFO Number: PAR-23-090
Wednesday, February 8, 2023
Notice Type: PAR
This funding opportunity announcement (FOA) encourages applications for multi-center clinical trials focused on neurological emergencies. Successful applicants will collaborate and conduct the trial within the NIH SIREN Network. The NIH SIREN Clinical Coordinating Center (CCC) will work with the successful applicants to implement the proposed trial efficiently and the SIREN Data Coordinating Center (DCC) will provide statistical and data management support. The NIH SIREN hubs and their affiliated clinical sites will provide on-site implementation of the clinical protocols.The NIH SIREN Network will also be uniquely poised to collaborate with other US and international consortia necessary to conduct larger, definitive trials of promising interventions for neurological emergencies. Multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS will be conducted in the NIH StrokeNet, and not within SIREN. Applicants do not need to be part of the existing SIREN infrastructure to apply under this FOA.
Notice of Special Interest (NOSI): Advancing Research for Tickborne Diseases (TBDs)
Expiration Date: Thursday, January 8, 2026
NOFO Number: NOT-AI-23-013
Friday, November 25, 2022
Notice Type: Notice of Special Interest
The purpose of this Notice is to announce that the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute of Mental Health (NIMH), the National Institute of Neurological Disorders and Stroke (NINDS), and the National Center for Complementary and Integrative Health (NCCIH) encourage new applications to advance research activities relevant to the five strategic priorities identified in the recently released NIH Strategic Plan for Tickborne Disease Research: